Want to see QTTB full AI Analyst Report?

Q32 Bio (QTTB) Price & Analysis

1,041 Followers

QTTB Stock Chart & Stats

$16.32

-$0.23(-1.50%)

At close: Jul 24 4:00 PM EDT

$16.32

-$0.23(-1.50%)

Day’s Range― - ―

52-Week Range$1.91 - $23.57

Previous CloseN/A

Volume178.84K

Average Volume (3M)911.21K

Market Cap

$245.00M

Enterprise Value$158.19M

Total Cash (Recent Filing)$106.27M

Total Debt (Recent Filing)$5.30M

Price to Earnings (P/E)3.0

Beta0.19

Next Earnings

Nov 05, 2026

EPS Estimate

-0.33

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)2.79

Shares Outstanding29,769,466

10 Day Avg. Volume1,552,344

30 Day Avg. Volume911,207

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)0.97

Price to Sales (P/S)0.76

P/FCF Ratio-1.22

Enterprise Value/Market Cap0.65

Enterprise Value/Revenue2.94

Enterprise Value/Gross Profit2.95

Enterprise Value/Ebitda4.57

Forecast

1Y Price Target

$38.86

Price Target Upside138.10% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)-1.49

Revenue Forecast (FY)$400.00K

Bulls Say, Bears Say

Bulls Say

Clinical Efficacy And DurabilityBempikibart’s Phase 2a efficacy, durability signals, and generally well-tolerated safety profile support advancement into registration-directed studies. Positive results across severe disease and prior JAK inhibitor exposure could broaden the program’s clinical relevance if confirmed in later trials.

Experienced Late-stage LeadershipThe additions of José Trevejo and Ellie Hershberger strengthen expertise as Q32 Bio moves toward late-stage development. Their backgrounds in regulatory approval, Phase 3 execution, and drug commercialization may improve the company’s ability to design and advance registration-directed studies.

Improved Balance Sheet PositionLow current debt relative to equity and the reported loan termination provide a healthier capital structure than in 2024. Reduced leverage can preserve financial flexibility for clinical development and limit debt-related constraints while the company advances its lead program.

Bears Say

No Established Product RevenueBecause Q32 Bio remains focused on clinical development rather than selling approved products, it lacks an established commercial revenue base to fund operations. Financial progress therefore depends heavily on advancing candidates successfully and securing external or strategic funding.

Persistent Cash BurnNegative operating and free cash flow show that the business is not self-funding despite improved reported profitability. Continued development spending may require additional financing, leaving the company exposed to funding needs and reducing certainty around its available development runway.

Volatile Historical Financial PerformanceLarge swings in revenue and earnings, including deep losses in earlier years, weaken confidence that recent reported profitability reflects durable operating performance. Historical equity instability adds further uncertainty to capital planning and the consistency of future financial results.

Q32 Bio News

Q32 Bio Inc trading resumes

09:35 EDT Q32 Bio (QTTB) Inc trading resumes Published first on TheFly – the ultimate source for real-time,...

6d ago

QTTB

Q32 Bio Inc trading halted, volatility trading pause

09:30 EDT Q32 Bio (QTTB) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate...

6d ago

QTTB

Q32 Bio anncounces results from Part B of the SIGNAL-AA Phase 2a clinical trial

Q32 Bio (QTTB) announced additional 36-week results and initial findings from the 16-week off-drug period from Part B...

6d ago

QTTB

Q32 Bio initiated with a Buy at Clear Street

Clear Street initiated coverage of Q32 Bio (QTTB) with a Buy rating and $38 price target The firm...

8d ago

QTTB

Q32 Bio initiated with a Buy at Jefferies

Jefferies analyst Maury Raycroft initiated coverage of Q32 Bio (QTTB) with a Buy rating and $29 price target...

8d ago

QTTB

UiPath, Pegasystems, Coinbase, Q32 Bio, BlackLine Trending by Analysts

Analysts are intrested in these 5 stocks: ( ($PATH) ), ( ($PEGA) ), ( ($COIN) ), ( ($QTTB)...

3d ago

COIN

Q32 Bio advances bempikibart in alopecia areata program

Q32 Bio ( ($QTTB) ) has provided an update. On September 30, 2026, Q32 Bio reported detailed 36-week...

6d ago

QTTB

Q32 Bio Appoints New Clinical and Development Leadership

Q32 Bio ( ($QTTB) ) has issued an update. On September 14, 2026, Q32 Bio announced the appointment...

22d ago

QTTB

These 2 ‘Monster Growth’ Stocks Aren’t Done Climbing, Say Analysts

Ask any old-school market investor and he’ll tell you that the cliché is true, and ‘past performance cannot...

1M ago

ANL

QTTB

Brinker, Whirlpool, Q32 Bio, Pulte, Janux Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($EAT) ), ( ($WHR) ), ( ($QTTB) ), ( ($PHM)...

1M ago

EAT

PHM

Q32 Bio initiated with an Overweight at Morgan Stanley

Morgan Stanley initiated coverage of Q32 Bio (QTTB) with an Overweight rating and $34 price target Q32 is...

1M ago

QTTB

Q32 Bio price target raised to $36 from $13 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Q32 Bio (QTTB) to $36 from $13 and keeps a...

2M ago

QTTB

Q32 Bio files to sell 6.88M shares of common stock for holders

16:15 EDT Q32 Bio (QTTB) files to sell 6.88M shares of common stock for holders Published first on...

3M ago

QTTB

Q32 Bio 6.03M share secondary priced at $18.25

The deal priced below last closing price of $18.46. Morgan Stanley, Jefferies, Cantor Fitzgerald, Oppenheimer and H.C. Wainwright...

3M ago

QTTB

QTTB FAQ

What was Q32 Bio’s price range in the past 12 months?

Q32 Bio lowest stock price was $1.91 and its highest was $23.57 in the past 12 months.

What is Q32 Bio’s market cap?

Q32 Bio’s market cap is $245.00M.

When is Q32 Bio’s upcoming earnings report date?

Q32 Bio’s upcoming earnings report date is Nov 05, 2026 which is in 30 days.

How were Q32 Bio’s earnings last quarter?

Q32 Bio released its earnings results on Aug 05, 2026. The company reported -$0.44 earnings per share for the quarter, beating the consensus estimate of -$0.542 by $0.102.

Is Q32 Bio overvalued?

According to Wall Street analysts Q32 Bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Q32 Bio pay dividends?

Q32 Bio does not currently pay dividends.

What is Q32 Bio’s EPS estimate?

Q32 Bio’s EPS estimate is -0.33.

How many shares outstanding does Q32 Bio have?

Q32 Bio has 29,769,466 shares outstanding.

What happened to Q32 Bio’s price movement after its last earnings report?

Q32 Bio reported an EPS of -$0.44 in its last earnings report, beating expectations of -$0.542. Following the earnings report the stock price went up 2.074%.

Which hedge fund is a major shareholder of Q32 Bio?

Currently, no hedge funds are holding shares in QTTB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Q32 Bio Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

75.25%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Q32 Bio

Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.

Q32 Bio (QTTB) Earnings & Revenues

Historic Earnings Reports

QTTB Stock 12 Month Forecast

Average Price Target

$38.86

▲(138.10% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","60":"$60","15.75":"$15.75","30.5":"$30.5","45.25":"$45.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":59,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$59.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38.857142857142854,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$38.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$29.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,15.75,30.5,45.25,60],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.25,12.153846153846153,16.057692307692307,19.96153846153846,23.865384615384613,27.76923076923077,31.673076923076923,35.57692307692308,39.480769230769226,43.38461538461539,47.28846153846154,51.19230769230769,55.09615384615385,{"y":59,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.25,10.604395604395604,12.958791208791208,15.313186813186812,17.667582417582416,20.021978021978022,22.376373626373624,24.730769230769226,27.085164835164832,29.439560439560438,31.79395604395604,34.14835164835164,36.50274725274725,{"y":38.857142857142854,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.25,9.846153846153847,11.442307692307693,13.038461538461538,14.634615384615385,16.230769230769234,17.826923076923077,19.423076923076923,21.01923076923077,22.615384615384617,24.211538461538463,25.80769230769231,27.403846153846153,{"y":29,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.08,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.81,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.82,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.32,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.98,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.95,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.11,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.04,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.66,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.68,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.36,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.25,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >